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Abstract
Laforin, encoded by a gene that is mutated in Lafora Disease (LD, OMIM 254780), is a modular protein composed of a
carbohydrate-binding module and a dual-specificity phosphatase domain. Laforin is the founding member of the glucan-
phosphatase family and regulates the levels of phosphate present in glycogen. Multiple reports have described the
capability of laforin to form dimers, although the function of these dimers and their relationship with LD remains unclear.
Recent evidence suggests that laforin dimerization depends on redox conditions, suggesting that disulfide bonds are
involved in laforin dimerization. Using site-directed mutagenesis we constructed laforin mutants in which individual
cysteine residues were replaced by serine and then tested the ability of each protein to dimerize using recombinant protein
as well as a mammalian cell culture assay. Laforin-Cys329Ser was the only Cys/Ser mutant unable to form dimers in both
assays. We also generated a laforin truncation lacking the last three amino acids, laforin-Cys329X, and this truncation also
failed to dimerize. Interestingly, laforin-Cys329Ser and laforin-Cys329X were able to bind glucans, and maintained wild type
phosphatase activity against both exogenous and biologically relevant substrates. Furthermore, laforin-Cys329Ser was fully
capable of participating in the ubiquitination process driven by a laforin-malin complex. These results suggest that
dimerization is not required for laforin phosphatase activity, glucan binding, or for the formation of a functional laforin-
malin complex. Cumulatively, these results suggest that cysteine 329 is specifically involved in the dimerization process of
laforin. Therefore, the C329S mutant constitutes a valuable tool to analyze the physiological implications of laforin’s
oligomerization.
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Introduction
Laforin is a 331 amino acid protein encoded by the EPM2A
gene. Mutations in EPM2A result in a rare, progressive myoclonus
epilepsy called Lafora disease (LD, OMIM 254780) [1,2]. LD is an
autosomal, recessive neurological disorder of devastating effects
that appears at early adolescence and manifests through epileptic
crises, myoclonus, tonic-clonic seizures, and a progressive demen-
tia, apraxia, aphasia and visual loss [3]. Patients usually die within
ten years of the first symptoms, and no effective clinical treatment
has yet been found. At the molecular level, the most characteristic
hallmark of LD is the formation of intracellular polyglucosan
inclusions called Lafora bodies (LBs), first described in neurons but
later found in many other tissues (mainly skeletal muscle, skin and
liver) [4]. LBs are poorly branched polyglucosans that are less
water-soluble than normal glycogen. Additionally, LBs contain
ubiquitin and a certain amount of sequestered proteins related to
the chaperone and proteasome systems [5]. Laforin has been
described as a glucan phosphatase capable of removing phosphate
from glycogen [6–9], and a direct link between laforin loss of
function and LBs formation has been suggested [7,8,10,11]. LBs
contain excess phosphate compared to normal glycogen [7,12–
14]. The source of this phosphate is currently under investigation.
One paper recently reported that glycogen synthase makes an
error in 1/10,000 glucose units so that a phosphate moiety is
introduced [15]; however, a more recent report called these results
into question [16]. Nonetheless, one of the functions of laforin is to
remove the phosphate so that glycogen branches appropriately
and does not form LBs. However, no consensus has been reached
as to whether LBs cause the neurological symptoms of LD
patients, or if LBs are just the consequence of prior abnormalities
affecting glycogen metabolism and protein clearance processes
that drastically alter neuronal function and finally result in LBs
formation [8,17,18].
The complexity of LD molecular etiology increased with the
discovery of another affected locus, EPM2B, in approximately half
of the cases [19,20]. EPM2B encodes malin, an E3-ubiquitin ligase
of the RING type. Data from multiple labs demonstrate that malin
and laforin physically interact and that this interaction is required
for ubiquitination of laforin itself [21] and other glycogen-related
substrates such as the muscle isoform of glycogen synthase (MGS)
[22], glycogen debranching enzyme (GDE) [23], and the
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glycogenic regulatory subunits of PP1 (type 1 protein phosphatase)
both R5/PTG (Protein Targeting to Glycogen) as well as R6
[24,25]. The implication of laforin and malin in glycogen
metabolism - either by means of a direct glycogen dephosphor-
ylation executed by laforin, by the ubiquitination of glycogenic
regulators through the laforin-malin complex, or by a balanced
participation of both processes - has guided research in LD over
the last several years. Additionally, recent work has described
novel relations between laforin, malin and other proteins involved
in protein clearance systems [5,26–28]. Moreover, the effects of
laforin-malin abnormalities produce autophagy impairment and
ER stress in animal models [29–32].
Laforin is classified in the family of atypical Dual Specificity
Phosphatases (atypical DSPs), which belong to the larger Protein
Tyrosine Phosphatase (PTP) superfamily [33,34]. All proteins in
the PTP superfamily share the presence of a signature catalytic
motif that encompasses a catalytic cysteine residue (HCxxxxxRS/
T, C266 in laforin). This motif is situated in a structurally
conserved catalytic domain called the dual specificity phosphatase
domain (DSP). The DSP domain is often accompanied by one or
more accessory domains that provide different substrate specificity
and interaction properties. In this sense, laforin is unique since it is
the only PTP member that consists of a DSP domain attached to a
carbohydrate-binding module (CBM) [35]. Recombinant laforin is
an active phosphatase that can dephosphorylate phospho-tyrosine,
phospho-serine/threonine and phospho-glucans in vitro [6,35,36].
However, no physiological proteinaceous substrate for laforin has
yet been defined.
To date, no crystal structure of laforin has been determined and
thus the specific properties and relative positions of the N-terminal
CBM and the C-terminal DSP domain remain uncertain.
Interestingly, laforin was found to dimerize both in vitro and in vivo
and it was postulated that dimerization was a functional feature of
the protein that regulated its phosphatase activity [37]. However,
previous work in our lab and others showed that laforin activity
does not depend on dimerization, and that laforin is present
mainly as a monomer under reduced conditions [38]. We
demonstrated that laforin dimerization is sensitive to redox
conditions, and addition of a reducing agent to samples results
in a predominance of monomeric laforin. On the contrary,
oxidative conditions increase not only the formation of dimers but
also of high molecular weight aggregates [39]. These redox
requirements suggested that intermolecular laforin disulfide bonds
may be responsible for dimerization. Thus, we decided to
elucidate the specific cysteine residues that are necessary for
laforin dimerization. Towards this goal, we mutated each laforin
cysteine residue to a serine and tested if the Cys/Ser mutant
protein could dimerize. We identified Cys329 as a residue that is
necessary for laforin dimerization. Per our predictions, laforin-
C329S that is unable to dimerize still maintains the main
functional properties of wild type laforin: 1) the ability to bind
carbohydrates, 2) phosphatase activity, and 3) the ability to bind
malin and participate in malin-directed ubiquitination.
These results have accomplished two complementary goals:
first, we determined that Cys329 is necessary for laforin
oligomerization; and second, we have obtained an exclusively
monomeric form of laforin. This monomeric form of laforin can
now be utilized as a valuable tool to elucidate the specific function
of laforin dimers in the pathophysiology of Lafora disease as well
as being utilized in crystallographic studies to determine the
tertiary structure of this protein.
Methods
Sequence Analysis
For the creation of a multiple amino acid sequence analysis,
sequence of human laforin was used as query for the retrieval of
entries from the UniprotKB database (a complete list of the
sequences used is shown in Table S1). Alignment of sequences was
performed using ClustalW [40] and manually edited with Bioedit
[41].
Structural Modeling of Laforin Domains
To generate a homology model of the laforin CBM and DSP,
we first used BLASTp to obtain the appropriate structural
templates. The sequence of each domain was analyzed via
BLASTp against the PDB database. The top hit for the laforin
CBM was glucoamylase (PDB ID: 1ACZ) [42] and the top hit for
the DSP domain was SEX4 (PDB ID: 3NME) [43]. The sequences
for the top ten hits for each domain were then aligned individually
with the laforin sequence using PROMALS3D [44], and the
resulting alignments were manually inspected for positional
matching in residues that are known to be critical for CBM and
DSP function. SWISS-MODEL was used to generate the laforin
homology models, and the models were assessed using Anolea,
Gromos, QMEAN6, DFire, and Verify3D [45–47]. Multiple
models were generated and each model was analyzed to determine
which BLASTp hits generated the best models. In each case, the
top BLASTp hit yielded the best homology model. Images were
generated using PyMol. Twenty residues in the C-terminus of the
laforin DSP model, which includes Cys329, are unstructured in
the model due to the absence of homology with the DSP of SEX4.
Plasmids and Mutagenesis
Human laforin DNA was amplified using pEG202-laforin [25]
as a template, using NdeI and NotI as the flanking sites; pET21b+-
laforin C109S/110S, C123S, C169S, C205S, C250S, C266S,
C278S and C329S were obtained by site directed mutagenesis
using plasmid pET21b+-laforin as template, the Quick Change kit
(Stratagene) and the corresponding mutagenic oligonucleotides.
These mutagenic nucleotides contained the corresponding 21
nucleotides upstream the codon to be mutagenized and the
downstream 21 nucleotides (45 nucleotides in total; see Table S2),
based on the human laforin cDNA. Nucleotides in the mutated
codon were replaced by the appropriated nucleotides to code for
Ser. All mutants were sequenced to ensure that additional
mutations were not introduced during the mutagenesis procedure.
Similarly, plasmid pCMV-HA laforin (C329S) was obtained by
site directed mutagenesis using plasmid pCMV-HA laforin [48] as
template, the Quick Change kit (Stratagene) and the correspond-
ing mutagenic oligonucleotides aforementioned. Plasmids
pCDNA3-HA-malin and pCMV-myc-R5/PTG are described in
[25] and pCMV-6xHisUbiq was from Dr. Manuel Rodriguez,
Proteomics Unit, CIC-BioGUNE, Vizcaya, Spain. Plasmids
pACT2-malin and pEG202-laforin are described in [25].
Protein Purification and Phosphatase Assays
Escherichia coli DH5a was used as the host strain for plasmid
constructions. E. coli BL21 (RIL) was used for protein production.
They were grown in LB (1% peptone, 0.5% yeast extract, 1%
NaCl, pH 7.5) medium supplemented with 50 g/L ampicillin and
30 g/L chloramphenicol. Transformants were grown at 37uC
until the absorbance at 600 nm reached a value of around 0.3.
IPTG was then added to a final concentration of 0.1 mM, and
cultures were maintained at 37uC for 3 h. Cells were harvested
and resuspended in 20 mL of sonication buffer [100 mM Tris-
Laforin Dimerization Requires Cysteine 329
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e69523
HCl pH 7.5, 150 mM NaCl, 2 mM PMSF and complete protease
inhibitor cocktail (Roche)]. Cells were disrupted by sonication and
the fusion proteins purified by passing the extracts through
columns containing 1 mL bed volume of amylose resin (N.E.
Biolabs). Recombinant proteins were eluted from the column with
500 mM maltose. Gel filtration chromatography was performed
using an AKTA Purifier with a HiLoad 16/60 Superdex 200 10/
300 GL size exclusion column (GE Healthcare).
In vitro phosphatase assays were performed using 4 mg of
recombinant proteins diluted in phosphatase buffer (0.1 M Tris-
HCl, 40 mM NaCl, 10 mM DTT), in the presence of 0.5 mM 3-
O-methyl fluorescein phosphate (OMFP, Sigma). Reactions were
carried out at 37uC in a final volume of 200 ml in 96-well ELISA
plates. Phosphatase activity was measured for 3 hours as
absorbance at 490 nm. One Unit of phosphatase activity is
defined as the one unit of change in the absorbance at 490 nm per
min of assay. Values are expressed as specific activity (Units/mg of
protein).
Yeast Two-hybrid Analysis
Yeast THY-AP4 strain [MATa ura3 leu2 trp1 lexA::lacZ
lexA::HIS3lexA::ADE2] [49] was transformed with plasmids
pACT2-malin (GAD-malin) and pEG202-laforin (LexA-laforin)
or pEG202-laforin-C329S (LexA-laforin-C329S). Transformants
were grown in selective SC medium, and b-galactosidase activity
was assayed in permeabilized cells and expressed in Miller units as
in [50].
Cell Culture and Immunodetection
Human embryonic kidney (HEK293) cells were grown in
DMEM (Lonza) supplemented with 100 units/mL penicillin,
100 mg/mL streptomycin, 2 mM glutamine, 10% inactivated fetal
bovine serum (GIBCO). 1.56106 cells were plated onto 60 mm
culture dishes the day before transfection. Cells were transfected
with 1 mg of pCMVmyc-laforin plasmid using Lipofectamine 2000
(Invitrogen). Twenty-four hours after transfection, cells were
scraped on ice in lysis buffer [10 mM Tris-HCl pH 8; 150 mM
NaCl, 15 mM EDTA; 0.6 M sucrose, 0.5% nonidet P-40 (NP-40),
protease inhibitor cocktail (Roche), 1 mM PMSF, 50 mM NaF
and 5 mM Na2P2O7]. Cells were lysed by repeated passage
through a 25-gauge needle. To analyze proteins under non-
denaturing, non-reducing conditions, cell extracts (25 mg) were
diluted in SDS- and DTT-free loading buffer (125 mM Tris-HCl,
20% glycerol) [38] and analyzed by regular SDS-PAGE and
immunoblotting using an anti-myc, anti-HA (Sigma) or anti-
laforin [25] antibody.
Co-immunoprecipitation Analysis
HEK293 cells were transfected with pCMV-HA-malin and
pCMV-myc-laforin or pCMV-myc-laforin-C329S, or with the
corresponding empty plasmid. Cells were scraped on ice in lysis
buffer [50 mM Tris-HCl pH 8; 10 mM KCl, 50 mM EDTA;
15% glycerol, 1% nonidet P-40 (NP-40), complete protease
inhibitor cocktail (Roche Diagnostics, Barcelona, Spain), 1 mM
PMSF, 50 mM NaF, 2 mM NaVO4 and 5 mM Na2P2O7]. Cell
lysates were then centrifuged at 13,0006g for 15 min at 4uC.
Laforin-malin complexes were immunoprecipitated from super-
natants (800 mg of total protein) with anti-myc polyclonal antibody
(Sigma–Aldrich, Madrid, Spain) and visualized by immunoblot-
ting using anti-myc or anti-HA (Sigma–Aldrich, Madrid, Spain)
antibodies.
Analysis of Ubiquitination
To study ubiquitination in intact cells, HEK293 cells were
transfected with plasmids pCMV-6xHisUbiq (encoding a modified
ubiquitin, tagged with 6xHis residues), plasmids encoding laforin
and the E3-ubiquitin ligase malin and pCMVmyc plasmids
encoding the protein of interest, using the Lipofectamine 2000
reagent (Invitrogen, Madrid, Spain), according to the manufac-
turers instructions. After 36 hours of transfection, cells were lysed
in buffer A (6 M guanidinium-HCl, 0.1 M sodium phosphate,
0.1 M Tris-HCl, pH 8.0). 1 mg of protein of a clarified extract
(CE; 12,0006g, 15 min) were incubated in 100 ml TALON
column (Clontech, Barcelona, Spain) in the presence of 10 mM
imidazole, for 3 hours at room temperature on a rocking platform,
to purify His-tagged proteins. The column was then successively
washed with 2 mL each of buffer B (buffer A plus 10 mM
imidazole), buffer C (buffer B, but with 8 M urea instead of 6 M
guanidinium-HCl) and four more times with buffer C adjusted to
pH 6.0. Bound proteins were eluted with 50 ml of 26Laemmli’s
sample buffer and analyzed by Western blotting using appropriate
antibodies.
Statistical Analysis
Values are given as means 6 SD of at least three independent
experiments. Differences between phosphatase activities of wt
laforin and mutant forms are analyzed by two-tailed student’s t-
test. The significance has been considered at *p,0.05, **p,0.01
and ***p,0.001, as indicated in each case. Data for protein
purification, gel electrophoresis, and ubiquitination is representa-
tive of at least three independent determinations.
Results
Identification and Mutagenesis of Cysteine Residues
We first sought to define the relative position and degree of
evolutionary conservation for each cysteine residue in human
laforin. Therefore, we generated a multiple sequence alignment of
laforin orthologs from different phyla. Laforin has an interesting
evolutionary lineage that has been previously thoroughly described
[9,51]. A gene encoding laforin is conserved in all analyzed
vertebrate genomes, but the laforin gene is absent from most
invertebrate and protozoan genomes, including the common
model organisms of yeast, worm, and fly. However, a gene
encoding laforin is found in the cnidarian Nematostella vectensis and
the protozoan Toxoplasma gondii. Based on the previously described
phylogeny, amino acid sequences of laforin orthologs from several
vertebrate organisms, one cnidarian, and one protozoon (see
Methods for a list of entries) were selected and aligned using
ClustalW. The resulting alignment shows a high degree of
conservation, especially in the DSP domain. Human laforin
contains nine cysteine residues, three of them located in the CBM
(C109, C110 and C123) and six in the DSP (C169, C205, C250,
C266, C278 and C329) (Figure 1). Only the position of C169 and
C266 is conserved in all sequences, although most of the
vertebrate orthologs share all nine cysteines along their primary
sequence (Figure 1A). C266 is the critical catalytic activity residue
[35], and it has previously been described that mutation of it to
Serine (C266S) abolishes phosphatase activity, but does not affect
laforin dimerization [38,52].
Next, we generated homology models (see Methods) to estimate
the location and solvent accessibility of each cysteine residue. The
cysteine residues located in the CBM appear located in a surface
exposed site and far from the residues involved in carbohydrate
binding (Figure 1C). In the DSP domain, C169, C205, C250 and
C329 are predicted to be located in a more surface exposed
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location, whereas the rest of residues are predicted to be buried in
the structure. Since neither the primary sequence nor the tertiary
structure analysis suggested a clear and unique candidate residue
responsible for dimerization, and in order to determine the
implication of each cysteine in the formation of dimers, we created
laforin mutants that changed individual cysteine residues to serine.
With this strategy we obtained eight mutant forms: seven
individual mutations (C123S, C169S, C205S, C250S, C266S,
C278S and C329S) and one double mutation (C109S/110S). This
latter form was created in order to avoid a possible masking effect
of cysteines C109 and C110 because of their close proximity. The
mutant proteins were then expressed in E. coli with no epitope tag
and recombinant mutant proteins were purified by affinity
purification using an amylose resin. This methodology presents
two advantages: first, it avoids the necessity of adding any tag in
the purified protein, due to the natural capacity of laforin to bind
carbohydrates; and second, it serves as a test of CBM functionality
in each laforin mutant. All mutant proteins were successfully
purified using this strategy with the exception of C278S. In this
case, we were unable to obtain any recombinant protein from E.
coli. In fact, laforin-C278S did not even express in E. coli and we
did not observe laforin-C278S in either the soluble or the pellet
fraction from the bacterial extracts. We also attempted to express
laforin-C278S in a yeast model but again, we were unable to
recover laforin-C278S from this system either. For this reason, the
mutant form of laforin C278S was not further studied in this work.
The rest of the seven mutants resulted in soluble proteins that all
bound the amylose resin.
Functional Analysis of Cysteine Mutants
Since each of the seven laforin mutants that were expressed in
E. coli all bound the amylose resin, we concluded that laforin
cysteines in either the CBM or the DSP domain are not necessary
to promote carbohydrate binding. This result is not surprising
since glucan binding is often driven by aromatic residues in CBMs
[35,53]. Next, we wanted to determine the integrity of the DSP
domain of each mutant using in vitro phosphatase assays with the
artificial substrate OMFP. Wild type and C266S mutant were used
as positive and negative controls of activity, respectively. As shown
in Figure 2A, most of the laforin mutants displayed decreased
phosphatase activity with the exception of C329S that exhibited a
similar activity to wild type. All mutants dephosphorylated OMFP
with a maximum catalytic efficiency at pH 8, although mutant
forms C205S and C250S showed a stronger sensitivity to pH
changes (Figure 2B).
Recombinant Laforin-C329S Mutant is Present as a
Monomer
After defining the ability of the mutants to bind glucans and
determining their phosphatase activity, we defined the dimeriza-
tion capacity of each mutant. Previous studies have reported that
dimerization of recombinant laforin can be assayed by electro-
phoresis in non-denaturing, non-reducing conditions (see Meth-
ods). Purified recombinant protein samples were analyzed by this
method, Western blotted, and detected using anti-laforin antibody
(Figure 3A). Interestingly, all mutant forms were able to dimerize,
with the exception of C329S that was present exclusively as a
monomer. Therefore, we further compared the oligomerization
capacity of wild type laforin and the C329S mutant form. Laforin
WT and C329S were first incubated with either a reducing agent
(DTT) or an oxidizing agent (hydrogen peroxide) and then
analyzed in the same way as described above. As expected, wild
type laforin appeared as an exclusively monomeric species in the
presence of DTT, but as a multimeric conglomerate of species in
the presence of hydrogen peroxide (Figure 3A, right panel).
Conversely, laforin-C329S appeared as an exclusively monomeric
form in both conditions (Figure 3A, right panel). To confirm the
absence of dimerization for laforin-C329S, we performed size-
exclusion chromatography. Laforin-C329S produced in bacteria
was purified using amylose-resin as described above. Immediately
after purification, the sample was loaded onto an analytical size-
exclusion column (Superdex 200) using a FPLC. Laforin-C329S
eluted as a single peak corresponding to a relative molecular
weight of 32.5 kDa, coincident with the estimate for monomeric
laforin (Figure 3B). A sample of the fraction corresponding to this
peak was then used in a non-reducing PAGE where we confirmed
that no dimeric forms appeared. After purifying monomeric
laforin-WT and laforin-C329S we then tested the phosphatase
activity of each protein and found that laforin-C329S had
phosphatase activity comparable to monomeric laforin-WT
(Figure 3C).
Next, we sought to determine if laforin-C329S could dimerize in
a cell culture model. Laforin-C329S was overexpressed in
HEK293 mammalian cells, cells were lysed, and crude extracts
were subjected to non-denaturing, non-reducing electrophoresis as
described above. As shown in Figure 3D, wild type protein
clearly forms both a monomeric and dimeric species, whereas
laforin-C329S only appears as a monomer. These results closely
mimic the data observed from bacterial expression. Cumulatively,
these data demonstrate that laforin-C329S displays reduced
dimerization while maintaining carbohydrate binding and phos-
phatase activity.
Recombinant Laforin-C329X does not Dimerize but
Maintains Carbohydrate Binding and Phosphatase
Activity
To further explore the effect of mutating Cys329 of laforin, we
generated a laforin construct lacking the last three amino acids,
laforin-C329X. Unlike the other constructs, laforin-C329X was
expressed with an amino-terminal HIS6 epitope tag that was used
during Ni-NTA purification.
Similar to laforin-C329S, laforin-C329X eluted from the size
exclusion Superdex 200 column as a single, monomeric peak of
,32.5 kDa (Figure 4A). Alternatively, wild type laforin with an
amino-terminal HIS6 epitope eluted as two peaks. We then
analyzed wild type and laforin-C329X under non-reducing PAGE
conditions and found that wild type laforin formed a monomer
Figure 1. Human laforin contains nine cysteines. (A) Multiple sequence alignment of laforin orthologs. Sequences of several vertebrate
(indicated by the brackets) and two invertebrate (N. vectensis and T. gondii) organisms were used (see Table S1 for details). The different cysteines are
highlighted in yellow, and the position of cysteines in human laforin is marked (catalytic cysteine C266 appears in red). (B) Schematic of laforin
domains (CBM: carbohydrate binding module; DSPD: dual-specificity phosphatase domain). The location of the nine cysteines is shown (blue
numbers). (C) Tertiary structure prediction of the CBM (left) and DSPD (right) laforin domains. Homology models were created using the structures of
glucoamylase (PDB: 1ACZ) and SEX4 (PDB: 3NME) as templates for the CBM and DSPD, respectively. The models were used to estimate the possible
location of the cysteines in the tertiary structure. The cysteines studied in this work appear in yellow in the CBM and in orange in the DSPD; in grey,
known tryptophans responsible of the carbohydrate binding.
doi:10.1371/journal.pone.0069523.g001
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and dimer, while laforin-C329X was largely monomeric
(Figure 4B).
After determining that laforin-C329X behaved similar to
laforin-C329S with respect to dimerization, we then sought to
determine the biochemical properties of laforin-C329X. First, we
tested if laforin-C329X could bind glucans. We utilized a
previously established glucan-binding assay for these experiments
[9,51,54]. As a negative control, we utilized the human
phosphatase Vaccinia virus phosphatase VH1-related (VHR), a
prototypical protein phosphatase that does not bind amylopectin
[9,54,55]. Recombinant proteins were incubated with amylopec-
tin, the amylopectin was then pelleted by ultracentrifugation, and
proteins in the pellet (P) and supernatant (S) were visualized by
Western analysis. As expected, VHR was found in the supernatant
whereas wild type laforin, which possesses robust glucan binding,
is in the pellet with the amylopectin (Figure 4C). Laforin-C329X
also robustly binds amylopectin, and similar to wild type laforin is
in the pellet. Next, we tested the phosphatase activity of laforin-
C329X and found that it too possesses similar phosphatase activity
against OMFP as wild type laforin (Figure 4D). Lastly, we tested
the ability of laforin-C329X to remove inorganic phosphate from
the phosphorylated glucan amylopectin. Potato amylopectin
contains levels of mono-esterified phosphate that when released
as inorganic phosphate can be detected using malachite green
assay. This method measures the biologically relevant activity of
laforin, i.e. its glucan phosphatase activity [6,9,55]. Per our
predictions, laforin-C329X dephosphorylated amylopectin to a
similar extent as wild type laforin (Figure 4E). Therefore, laforin-
C329X exhibits a dramatic decrease in dimerization compared to
wild type laforin while maintaining wild type levels of glucan
binding and both generic and biologically relevant phosphatase
activities.
These results confirm that mutation of Cys329 abrogates the
propensity of laforin to form dimers. This finding prompted us to
assess the effects of mutating Cys329 using a mammalian cell
model in order to define the implications of laforin oligomerization
in a more biologically relevant system.
Laforin C329S Forms a Functional Complex with Malin in
Mammalian Cells
As discussed in the introduction, laforin forms a complex with
the E3 ubiquitin ligase malin that ubiquitinates multiple substrates
involved in glycogen metabolism. We previously defined that
laforin dimerization was not required for the interaction between
laforin and malin [38]. Therefore, we reasoned that co-expression
of laforin C329S and malin should result in normal ubiquitination
of the substrates defined for the laforin-malin complex, such as
protein targeting to glycogen R5/PTG [25].
First, we proceeded to test if laforin-C329S was still able to
physically interact with malin. We analyzed this interaction by
yeast two-hybrid analysis and found no significant differences
between the interaction of laforin WT and C329S with malin
(Figure 5A). Next, we co-transfected HEK293 cells with HA-
malin and myc-laforin (WT or C329S). Both laforin forms were
able to co-immunoprecipitate HA-malin, corroborating that
mutation of Cys329 does not affect the physical interaction
between laforin and malin (Figure 5B). Then, we transfected HA-
tagged laforin WT or C329S into HEK293 cells together with
HA-malin, myc-tagged R5/PTG [25] and a HIS6-tagged ubiqui-
tin plasmid. Ubiquitinated proteins from crude extracts were
purified using a metal affinity resin as previously described [56]
and the ubiquitination of the substrate was analyzed by Western
analysis. Ubiquitination occurred in a malin-dependent manner
when either wild type laforin or laforin-C329S was present;
however, no R5/PTG ubiquitination occurred in the absence of
both wild type laforin and laforin-C329S (Figure 5C). This result
demonstrates that laforin-C329S, that does not dimerize, is still
able to form a functional complex with malin and promotes the
ubiquitination of R5/PTG.
Discussion
Laforin, the dual-specificity phosphatase mutated in Lafora
disease, is intimately involved in mechanisms leading to abnormal
glycogen accumulation, autophagy impairment, and other molec-
ular abnormalities that underlie Lafora disease. However, many
Figure 2. Functional analysis of laforin mutants. (A) Recombinant proteins expressed in bacteria were purified using an amylose resin and used
for in vitro phosphatase assays employing the artificial substrate OMFP. The mutant C266S was used as a negative control. (B) The same samples were
used in phosphatase assays using different pH conditions and represented as % phosphatase activity compared to the pH of maximum activity of
each mutant (pH = 8 in all cases). Error bars represent SD of three independent measurements; statistical significance refers to the activity of wt
protein (*p,0.05, **p,0.01 and ***p,0.001).
doi:10.1371/journal.pone.0069523.g002
Laforin Dimerization Requires Cysteine 329
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e69523
Figure 3. Laforin-C329S is monomeric. (A) In vitro dimerization assay. Recombinant proteins expressed in bacteria were purified and subjected
to non-reducing, non-denaturing electrophoresis and were immunodetected using anti-laforin antibody. All mutants could form dimers with the
exception of C329S (left panel). WT laforin and C329S were further analyzed by incubation in the presence of 10 mM DTT or 10 mM H2O2 and
analyzed for the presence of monomeric and dimeric species (right panel). (B) Laforin C329S exclusion chromatography analysis. A single peak is
observed in an elution volume corresponding to 32.5 kDa (molecular size markers are indicated). (C) In vitro phosphatase activity assay of the same
sample showed that the C329S mutant displayed a catalytic activity comparable to the wild type protein. (D) In vitro dimerization assay of laforin-
C329S expressed in mammalian cells. Crude lysates from HEK293 cells transfected with myc-laforin (wt, wild type) or myc-C329S plasmids were
analyzed by Western blot. The electrophoresis was carried out in non-reducing, non-denaturing conditions, and the immunodetection was
performed using anti-laforin antibody. The position of the monomeric and dimeric forms of laforin is indicated.
doi:10.1371/journal.pone.0069523.g003
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Figure 4. Laforin-C329X does not dimerize, but maintains activity. (A) Laforin-C329X exclusion chromatography chromatogram.
Recombinant laforin-C329X was purified via affinity chromatography and then subjected a HiLoad 16/60 Superdex 200 sizing column. A single peak
elutes that corresponds to 32.5 kDA. (B) In vitro dimerization assay. Recombinant laforin-WT and laforin-C329X were purified via affinity
chromatography, subjected to non-reducing, non-denaturing electrophoresis, and immunoblotted using anti-HIS antibody. (C) Co-sedimentation
assay of protein and amylopectin (amylopectin binding assay). Recombinant histidine-tagged proteins were incubated with 5 mg/ml amylopectin,
amylopectin was pelleted by ultracentrifugation, proteins in the pellet (P) and supernatant (S) were separated by SDS-PAGE, and visualized by
Western analysis. Amylopectin-bound proteins are found in the pellet (P) and unbound proteins are found in the supernatant (S).VHR, Vaccinia virus
phosphatase VH1-related; WT, laforin; C329X, laforin-C329X. (D) Recombinant laforin-WT, laforin-C329X, and laforin-C266S were purified and used for
in vitro phosphatase assays employing the artificial substrate OMFP. The mutant C266S was used as a negative control. (E) Recombinant laforin-WT,
laforin-C329X, and laforin-C266S were purified and used for in vitro phosphatase assays employing the phosphorylated glucan amylopectin.
Inorganic phosphate release was detected via malachite green.
doi:10.1371/journal.pone.0069523.g004
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biochemical and functional properties of laforin remain largely
unknown. Dual-specificity phosphatases are a broad family of
proteins that share little sequence conservation at the primary
amino acid level, but share a highly conserved catalytic domain
with respect to structure. Laforin is a unique DSP since it is the
only human protein of the group that contains a carbohydrate-
binding module. These unique attributes allow laforin to bind and
dephosphorylate glycogen. Additionally, laforin functions in a
complex with malin, and this complex participates in other cellular
functions besides dephosphorylation of glycogen.
The lack of structural data for laforin has constituted a severe
difficulty in assessing many of its particular features. For this
reason, indirect data regarding the structure and biochemical
properties of the domains that constitute the modular structure of
laforin are extremely useful. Like other structurally related small
phosphatases [57], laforin was reported to form dimers. However,
we recently described that laforin dimerization depends on redox
conditions, suggesting the involvement of disulfide bridges and
hence the participation of cysteine residues in the dimerization of
laforin [38]. In the present work, we have demonstrated that
cysteine 329 in human laforin is necessary for the formation of
Figure 5. Laforin-C329S and malin physically interact and form a functional complex in mammalian cells. (A) Yeast two-hybrid analysis.
THY-AP4 yeast strain was transformed with pACT2-malin and LexA-laforin (WT or C329S) and the interaction was assessed by measuring the b-
galactosidase activity. (B) Co-immunoprecipitation assay. HEK293 cells were co-transfected with plasmids myc-laforin (WT or C329S) and HA-malin.
Cells were lysed and total lysates were incubated with anti-myc antibody and protein A/G beads. After washing, beads were boiled in loading buffer
and purified proteins analyzed by SDS-PAGE and Western blot using anti-myc or anti-HA antibodies. (C) Ubiquitination analysis of R5/PTG by the
laforin-malin complex. Overexpression of 6xHis-ubiquitin, pCMV-HA-malin, pCMV-myc-R5/PTG and pCMV-HA-laforin (wild type or C329S) in HEK293
cells, followed by lysis in presence of guanidinium chloride and purification of the ubiquitinated proteins by affinity chromatography using a cobalt
resin. The result of the purification was analyzed using Western blot with anti-myc antibodies. Bound: proteins retained in the resin; crude extracts
(50 mgr, C.E.) were immunodetected with anti-HA antibodies. *: polyubiquitinated forms.
doi:10.1371/journal.pone.0069523.g005
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laforin dimers, both in bacterial and mammalian cell models, and
that dimerization of laforin is not required for its binding to
carbohydrates, its phosphatase activity, or ubiquitination of R5/
PTG by the laforin-malin complex.
Laforin dimerization is also observed in a functional equivalent
of laforin from plants called SEX4 [38]. Interestingly, SEX4 also
contains a Cys residue near its carboxy-terminus [43]. The
conservation of this mechanism across kingdoms as well as the
abundance of cysteines and the high conservation of the residues
flanking the cysteines suggested structural roles in which the thiol
group of the cysteine could be involved in intra- or inter-molecular
interactions. To assess if any of these residues participate in the
dimerization process, we performed site-directed mutagenesis of
each cysteine and changed each one to a serine. The Cys/Ser
mutation avoids the presence of a thiol group while maintaining
structural and chemical characteristics of the residue. C329S was
the only mutant that demonstrated impaired dimerization. Cys329
was observed in the majority of laforin orthologs examined and its
position near the carboxy-terminus of the protein makes it a good
candidate to form intermolecular disulphide bridges.
Recombinant laforin-C329S subjected to affinity purification
and size-exclusion chromatography resulted in an exclusively
monomeric form. Mutation of laforin Cys329 to Ser does not
disrupt overall protein structure because we demonstrate that
laforin-C329S maintains near wild type levels of phosphatase
activity and it maintains its ability to bind an amylose resin. In
addition to the experiments performed with laforin-C329S, we
also generated a truncated form of the protein. Laforin-C329X
was also a monomeric protein after size-exclusion chromatography
that retained the ability to bind glucans and the catalytical
properties of the wild type laforin against both OMFP as well as
against the phosphorylated glucan amylopectin. This suggests that
in humans, laforin C329 is necessary for the formation of dimers.
C329 is highly conserved among vertebrate orthologs, but it is not
strictly conserved outside of vertebrates. Thus, it may be possible
that laforin dimerization represents a functional aspect of laforin in
vertebrates. However, the functional equivalent of laforin in
plants, SEX4, has also been shown to dimerize [38]. Thus, it is
possible that dimerization is a conserved mechanism of glucan
phosphatases.
Laforin functionality is defined by two biochemical properties:
glucan phosphatase activity and the capacity to bind carbohy-
drates. Mutation of eight cysteine residues to serine did not impair
the ability of the mutant proteins to bind the amylose resin.
Therefore, these eight mutations did not affect the overall
structure of laforin. Mutation in the additional cysteine residue
C278 produced forms highly unstable that precluded its further
analysis, likely due to the predicted location of C278 deep within
one of the core helices structurally critical for the catalytic domain.
When the phosphatase activity of the eight mutants was analyzed,
a significant decrease in the catalytic activity of all mutant forms,
with the exception of C329S, was found, suggesting that
abrogation of thiol groups may affect the adequate conditions
for the full catalytic performance of laforin. The strict pH
requirement of catalytically impaired mutants, such as C205S and
C250S, further corroborates this observation.
Cumulatively, the data demonstrate that laforin cysteine 329
abrogates the capacity of laforin to form dimers without affecting
its ability to bind carbohydrates or its phosphatase activity.
Oligomerization of proteins may constitute a critical event to
define their interactions with other binding partners. Since the
physiological function of laforin in regulating glycogen synthesis is
tightly linked to its interaction with the E3-ubiquitin ligase malin,
we sought to determine if abrogation of laforin dimerization would
impede the interaction between malin and laforin. We found that
laforin-C329S binds to malin with the same efficiency as the wild
type protein, both in yeast and mammalian cell models. Moreover,
we found that laforin-C329S was able to ubiquitinate R5/PTG in
the same way as wild type protein, indicating that no dimerization
is required for the formation of a functional laforin-malin complex.
The implications of this finding are of importance, since no data
about the physiological implications of laforin oligomerization
have previously been defined. Laforin-C329S constitutes a
valuable tool to assess which laforin properties are dependent on
dimerization. Our data demonstrate that both wild type and
laforin-C329S maintain intact catalytic activity, ability to bind
carbohydrates, and the ability to interact with malin. In addition
to defining some of the physiological attributes of monomeric
laforin, the laforin-C329S and laforin-C329X may prove useful for
structural analysis. To date, the only structure of a glucan
phosphatase is of the plant protein SEX4 [43]. The exclusion
chromatography data of laforin-C329S and laforin-C329X
demonstrate that they are easily purified as monomeric species.
Historically, laforin has been very difficult to purify and crystallize
in large part due to its propensity to oligomerize and thus produce
heterogeneity in crystallographic screens. These issues have
delayed the success in determining the structure of the protein.
Laforin-C329S and –C329X, which are homogeneously mono-
meric, may aid in obtaining laforin crystals and provide a most
valuable advance in our understanding of the molecular basis of
Lafora disease.
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